Company Overview of Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a drug development company, develops small molecule therapeutics for the treatment of inflammatory and cardiovascular diseases. Its product includes a short-acting calcium channel antagonist for the treatment of transient cardiovascular conditions, such as atrial arrhythmias and angina. The company was founded in 2003 and is based in Montreal, Canada.
6100 Royalmount Avenue
Montreal, QC H4P 2R2
Founded in 2003
Key Executives for Milestone Pharmaceuticals Inc.
Chief Executive Officer and Director
Vice President of Chemistry & Manufacturing
Vice President of Drug Development
Compensation as of Fiscal Year 2014.
Milestone Pharmaceuticals Inc. Key Developments
Milestone Pharmaceuticals, Inc. Announces Positive Phase 1 Data for MSP-2017 and Supports Advancement into Phase 2 in PSVT Patients
Dec 2 14
Milestone Pharmaceuticals Inc. announced data from a Phase 1 clinical trial conducted in Melbourne, Australia of MSP-2017, a novel calcium channel antagonist for the potential treatment of paroxysmal supraventricular tachycardia (PSVT). The results demonstrated that an intra-nasal formulation of MSP-2017 was well tolerated at single doses up to and including 140 mg with an excellent safety profile, desirable PK properties including rapid onset, and validating proof of concept by PR interval prolongation as measured by ECG. Milestone expects to initiate a Phase 2 clinical trial of MSP-2017 in patients with PSVT during the first half of 2015. The Phase 1 clinical trial included a randomized, double-blind, placebo-controlled, single ascending-dose study in 56 healthy volunteers. The primary objective of the study was to evaluate the safety, tolerability and pharmacokinetics of two intranasal formulations of MSP-2017 in a crossover design given as a single dose to seven successive cohorts of 8 healthy subjects each. All adverse events were mild in nature and no serious adverse events were reported. The Phase 1 study was undertaken following promising results in the preclinical evaluation of MSP-2017. In a series of in vivo experiments, MSP-2017 exhibited prolongation of the PR interval as measured by ECG. These results suggest MSP-2017 can impact AV nodal conduction, and support the potential of MSP-2017 to treat PSVT episodes.
Milestone Pharmaceuticals Inc. Appoints Francis Plat as Chief Medical Officer
Jul 21 14
Milestone Pharmaceuticals Inc. announced the appointment of Francis Plat, MD, FAHA, as Chief Medical Officer of the company. Dr. Plat is a board-certified cardiologist with extensive experience in cardiovascular drug development. Most recently, Dr. Plat was Vice President and Therapeutic Area Head, Atherosclerosis and Cardiovascular at Merck Research Laboratories.
Milestone Pharmaceuticals Inc. Presents at BIO International Convention, Jun-24-2014 04:15 PM
Jun 17 14
Milestone Pharmaceuticals Inc. Presents at BIO International Convention, Jun-24-2014 04:15 PM. Venue: San Diego Convention Center, San Diego, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|